These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 26631606)
21. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
22. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA; Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508 [TBL] [Abstract][Full Text] [Related]
23. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Streff H; Profato J; Ye Y; Nebgen D; Peterson SK; Singletary C; Arun BK; Litton JK Oncologist; 2016 Jul; 21(7):869-74. PubMed ID: 27306910 [TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. Teixeira N; Mourits MJ; Vos JR; Kolk DM; Jansen L; Oosterwijk JC; Bock GH Maturitas; 2015 Oct; 82(2):197-202. PubMed ID: 26239500 [TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594 [TBL] [Abstract][Full Text] [Related]
27. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760 [TBL] [Abstract][Full Text] [Related]
29. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695 [TBL] [Abstract][Full Text] [Related]
30. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836 [TBL] [Abstract][Full Text] [Related]
31. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478 [TBL] [Abstract][Full Text] [Related]
32. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
33. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751 [TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
35. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S; N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660 [TBL] [Abstract][Full Text] [Related]
36. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. Vos JR; de Bock GH; Teixeira N; van der Kolk DM; Jansen L; Mourits MJ; Oosterwijk JC Eur J Cancer; 2013 Jun; 49(9):2101-6. PubMed ID: 23490645 [TBL] [Abstract][Full Text] [Related]
37. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates. Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222 [TBL] [Abstract][Full Text] [Related]
38. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077 [TBL] [Abstract][Full Text] [Related]
39. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174 [TBL] [Abstract][Full Text] [Related]
40. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]